Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Next Previous
Trial Profile

A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 16 Oct 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rotigotine (Primary) ; Rotigotine
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Luye Pharma Group

Most Recent Events

  • 13 Oct 2020 Status changed from recruiting to completed.
  • 19 Jun 2020 Planned End Date changed from 5 Aug 2020 to 10 Aug 2020.
  • 19 Jun 2020 Planned primary completion date changed from 21 Jun 2020 to 5 Aug 2020.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top